The DOI matches its Crossref record; 94 of the 94 references it cites were found in a registry or an index.
Anticancer cyclometalated complexes of platinum group metals and gold
Open accessAbstract
The clinical success of cisplatin and its derivatives has had an enormous impact on the discovery of novel metal-based drugs. Extensive studies have focused on the interaction of metal complexes with their potential targets. The array of organometallic compounds with useful anticancer activity has been significantly extended with respect to metals and structures. This review highlights recent exciting results in the field of cyclometalated C N complexes and C N C, C N N and C N S pincer complexes of platinum, palladium, gold, ruthenium, rhodium, and iridium with potential anticancer properties.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Structure, Recognition, and Processing of Cisplatin−DNA Adducts
Jamieson, E. R., & Lippard, S. J. (1999) · Chemical Reviews · doi:10.1021/cr980421n · Cited by 2,949
Targeting DNA topoisomerase II in cancer chemotherapy
Nitiss, J. L. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2607 · Cited by 1,791
Organometallic Anticancer Compounds
Gasser, G., Ott, I., & Metzler-Nolte, N. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm100020w · Cited by 1,624
New trends for metal complexes with anticancer activity
Bruijnincx, P. C., & Sadler, P. J. (2008) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2007.11.013 · Cited by 1,306
The Potential of Palladacycles: More Than Just Precatalysts
Dupont, J., Consorti, C. S., & Spencer, J. (2005) · Chemical Reviews · doi:10.1021/cr030681r · Cited by 1,300
Cisplatin: Chemistry and Biochemistry of a Leading Anticancer Drug
(1999) · Wiley eBooks · doi:10.1002/9783906390420 · Cited by 1,296
PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect
Acharya, S., & Sahoo, S. K. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.10.008 · Cited by 1,112
Bioorganometallic chemistry—from teaching paradigms to medicinal applications
Hartinger, C. G., & Dyson, P. J. (2009) · Chem. Soc. Rev. · doi:10.1039/b707077m · Cited by 985
Hartinger, C. G., Zorbas-Seifried, S., Jakupec, M. A., Kynast, B., Zorbas, H., & Keppler, B. K. (2006) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2006.02.013 · Cited by 956
Antitumour metal compounds: more than theme and variations
Jakupec, M. A., Galanski, M. S., Arion, V. B., Hartinger, C. G., & Keppler, B. K. (2008) · Dalton Transactions · doi:10.1039/b712656p · Cited by 850
Rademaker-Lakhai, J. M., van den Bongard, D., Pluim, D., Beijnen, J. H., & Schellens, J. H. M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0746 · Cited by 833
Hartinger, C. G., Jakupec, M. A., Zorbas‐Seifried, S., Groessl, M., Egger, A., Berger, W., Zorbas, H., Dyson, P. J., & Keppler, B. K. (2008) · Chemistry & Biodiversity · doi:10.1002/cbdv.200890195 · Cited by 830
On the medicinal chemistry of gold complexes as anticancer drugs
Ott, I. (2009) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2009.02.019 · Cited by 825
In Vitro and in Vivo Evaluation of Ruthenium(II)−Arene PTA Complexes
Scolaro, C., Bergamo, A., Brescacín, L., Delfino, R., Cocchietto, M., Laurenczy, G., Geldbach, T. J., Sava, G., & Dyson, P. J. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050015d · Cited by 784
Metal N-heterocyclic carbene complexes as potential antitumor metallodrugs
Liu, W., & Gust, R. (2013) · Chem. Soc. Rev. · doi:10.1039/c2cs35314h · Cited by 762
Targeting and delivery of platinum-based anticancer drugs
Wang, X., & Guo, Z. (2013) · Chem. Soc. Rev. · doi:10.1039/c2cs35259a · Cited by 684
Telomere maintenance as a target for anticancer drug discovery
Neidle, S., & Parkinson, G. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd793 · Cited by 624
Non Platinum Metal Complexes as Anti‐cancer Drugs
Ott, I., & Gust, R. (2007) · Archiv der Pharmazie · doi:10.1002/ardp.200600151 · Cited by 609
Thioredoxin reductase: A target for gold compounds acting as potential anticancer drugs
Bindoli, A., Rigobello, M. P., Scutari, G., Gabbiani, C., Casini, A., & Messori, L. (2009) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2009.02.026 · Cited by 595
Aird, R. E., Cummings, J., Ritchie, A. A., Muir, M., Morris, R. E., Chen, H., Sadler, P. J., & Jodrell, D. I. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600290 · Cited by 582
N-Heterocyclic carbene metal complexes in medicinal chemistry
Oehninger, L., Rubbiani, R., & Ott, I. (2013) · Dalton Trans. · doi:10.1039/c2dt32617e · Cited by 560
Inhibition of transcription by platinum antitumor compounds
Todd, R. C., & Lippard, S. J. (2009) · Metallomics · doi:10.1039/b907567d · Cited by 539
Approaching tumour therapy beyond platinum drugs
Bergamo, A., Gaiddon, C., Schellens, J. H. M., Beijnen, J. H., & Sava, G. (2012) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2011.09.030 · Cited by 514
Gold compounds as anticancer agents: chemistry, cellular pharmacology, and preclinical studies
Nobili, S., Mini, E., Landini, I., Gabbiani, C., Casini, A., & Messori, L. (2010) · Medicinal Research Reviews · doi:10.1002/med.20168 · Cited by 503
Gold compounds as therapeutic agents for human diseases
Berners-Price, S. J., & Filipovska, A. (2011) · Metallomics · doi:10.1039/c1mt00062d · Cited by 495
Ruthenium-based chemotherapeutics: are they ready for prime time?
Antonarakis, E. S., & Emadi, A. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-010-1293-1 · Cited by 489
Fuertes, M., Castilla, J., Alonso, C., & Pérez, J. (2003) · Current Medicinal Chemistry · doi:10.2174/0929867033368484 · Cited by 432
Metal based drugs: from serendipity to design
Fricker, S. P. (2007) · Dalton Transactions · doi:10.1039/b705551j · Cited by 414
Lo, K. K.-W., Choi, A. W.-T., & Law, W. H.-T. (2012) · Dalton Transactions · doi:10.1039/c2dt11892k · Cited by 386
Designing organometallic compounds for catalysis and therapy
Noffke, A. L., Habtemariam, A., Pizarro, A. M., & Sadler, P. J. (2012) · Chemical Communications · doi:10.1039/c2cc30678f · Cited by 370
Organometallic ruthenium-based antitumor compounds with novel modes of action
Ang, W. H., Casini, A., Sava, G., & Dyson, P. J. (2011) · Journal of Organometallic Chemistry · doi:10.1016/j.jorganchem.2010.11.009 · Cited by 366
Platinum Drug Distribution in Cancer Cells and Tumors
Klein, A. V., & Hambley, T. W. (2009) · Chemical Reviews · doi:10.1021/cr9001066 · Cited by 351
Kane, R. C., Farrell, A. T., Sridhara, R., & Pazdur, R. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0170 · Cited by 341
Hannon, M. J. (2007) · Pure and Applied Chemistry · doi:10.1351/pac200779122243 · Cited by 313
Ma, D.-L., Che, C.-M., & Yan, S.-C. (2009) · Journal of the American Chemical Society · doi:10.1021/ja806045x · Cited by 289
Exploring biologically relevant chemical space with metal complexes
Meggers, E. (2007) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2007.05.013 · Cited by 274
Casini, A., Hartinger, C., Gabbiani, C., Mini, E., Dyson, P. J., Keppler, B. K., & Messori, L. (2008) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2007.11.003 · Cited by 267
Marcon, G., Carotti, S., Coronnello, M., Messori, L., Mini, E., Orioli, P., Mazzei, T., Cinellu, M. A., & Minghetti, G. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm010997w · Cited by 266
Barnes, K. R., Kutikov, A., & Lippard, S. J. (2004) · Chemistry & Biology · doi:10.1016/j.chembiol.2004.03.024 · Cited by 263
Kelland, L. R. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2004.11.024 · Cited by 252
Organometallic Ruthenium(II) Arene Compounds with Antiangiogenic Activity
Nowak-Sliwinska, P., van Beijnum, J. R., Casini, A., Nazarov, A. A., Wagnières, G., van den Bergh, H., Dyson, P. J., & Griffioen, A. W. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm2002074 · Cited by 248
Metal-based antitumour drugs in the post-genomic era: what comes next?
Sava, G., Bergamo, A., & Dyson, P. J. (2011) · Dalton Transactions · doi:10.1039/c1dt10522a · Cited by 231
Metal complexes in medicine with a focus on enzyme inhibition
Che, C.-M., & Siu, F.-M. (2010) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2009.11.015 · Cited by 224
Muggia, F. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.09.034 · Cited by 221
Gold complexes inhibit mitochondrial thioredoxin reductase: consequences on mitochondrial functions
Pia Rigobello, M., Messori, L., Marcon, G., Agostina Cinellu, M., Bragadin, M., Folda, A., Scutari, G., & Bindoli, A. (2004) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2004.04.020 · Cited by 213
Organometallic Compounds: An Opportunity for Chemical Biology?
Patra, M., & Gasser, G. (2012) · ChemBioChem · doi:10.1002/cbic.201200159 · Cited by 213
Wang, A. H. J., Nathans, J., van der Marel, G., van Boom, J. H., & Rich, A. (1978) · Nature · doi:10.1038/276471a0 · Cited by 209
Meng, X., Leyva, M. L., Jenny, M., Gross, I., Benosman, S., Fricker, B., Harlepp, S., Hébraud, P., Boos, A., Wlosik, P., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4408 · Cited by 208
Activation Mechanisms for Organometallic Anticancer Complexes
Pizarro, A. M., Habtemariam, A., & Sadler, P. J. (2010) · Topics in Organometallic Chemistry · doi:10.1007/978-3-642-13185-1_2 · Cited by 199
Molecular Mechanisms and Proposed Targets for Selected Anticancer Gold Compounds
Casini, A., & Messori, L. (2011) · Current Topics in Medicinal Chemistry · doi:10.2174/156802611798040732 · Cited by 196
Rhodium(III) and iridium(III) complexes as anticancer agents
Geldmacher, Y., Oleszak, M., & Sheldrick, W. S. (2012) · Inorganica Chimica Acta · doi:10.1016/j.ica.2012.06.046 · Cited by 194
Peptide Targeted Lipid Nanoparticles for Anticancer Drug Delivery
Pearce, T. R., Shroff, K., & Kokkoli, E. (2012) · Advanced Materials · doi:10.1002/adma.201200832 · Cited by 192
Wai-Yin Sun, R., Lok-Fung Chow, A., Li, X.-H., Yan, J. J., Sin-Yin Chui, S., & Che, C.-M. (2011) · Chemical Science · doi:10.1039/c0sc00593b · Cited by 181
Cyclometalated gold(iii) complexes with N-heterocyclic carbene ligands as topoisomerase I poisons
Yan, J. J., Chow, A. L.-F., Leung, C.-H., Sun, R. W.-Y., Ma, D.-L., & Che, C.-M. (2010) · Chemical Communications · doi:10.1039/c001216e · Cited by 179
Lau, J. S.-Y., Lee, P.-K., Tsang, K. H.-K., Ng, C. H.-C., Lam, Y.-W., Cheng, S.-H., & Lo, K. K.-W. (2009) · Inorganic Chemistry · doi:10.1021/ic801818x · Cited by 174
A Metal‐Based Inhibitor of Tumor Necrosis Factor‐α
Leung, C., Zhong, H., Yang, H., Cheng, Z., Chan, D. S., Ma, V. P., Abagyan, R., Wong, C., & Ma, D. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201202937 · Cited by 164
Cysteine proteases as targets for metal-based drugs
Fricker, S. P. (2010) · Metallomics · doi:10.1039/b924677k · Cited by 144
Gaiddon, C., Jeannequin, P., Bischoff, P., Pfeffer, M., Sirlin, C., & Loeffler, J. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.089342 · Cited by 142
Gold(III) compounds as anticancer drugs
Gabbiani, C., Casini, A., & Messori, L. (2007) · Gold bulletin · doi:10.1007/bf03215296 · Cited by 142
A Metal‐Based Inhibitor of Tumor Necrosis Factor‐α
Leung, C., Zhong, H., Yang, H., Cheng, Z., Chan, D. S., Ma, V. P., Abagyan, R. A., Wong, C., & Ma, D. (2012) · Angewandte Chemie · doi:10.1002/ange.201202937 · Cited by 142
Casini, A., Kelter, G., Gabbiani, C., Cinellu, M. A., Minghetti, G., Fregona, D., Fiebig, H., & Luigi Messori, A. (2009) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-009-0558-9 · Cited by 138
Lo, Y., Ko, T., Su, W., Su, T., & Wang, A. H. ‐. (2009) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2009.05.006 · Cited by 130
Lo, K. K., Lee, P.-K., & Lau, J. S.-Y. (2008) · Organometallics · doi:10.1021/om800212t · Cited by 116
Inhibitory effects of a new oral gold compound on hela cells
Simon, T. M., Kunishima, D. H., Gj, V., & LORBER, A. (1979) · Cancer · Cited by 116
Sun, R. W., Lok, C., Fong, T. T., Li, C. K.-L., Yang, Z. F., Zou, T., Siu, F., & Che, C. (2013) · Chemical Science · doi:10.1039/c3sc21972k · Cited by 113
Gabbiani, C., Mastrobuoni, G., Sorrentino, F., Dani, B., Rigobello, M. P., Bindoli, A., Cinellu, M. A., Pieraccini, G., Luigi Messori, A., & Casini, A. (2010) · MedChemComm · doi:10.1039/c0md00181c · Cited by 110
Baruah, H., Barry, C. G., & Bierbach, U. (2004) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026043387313 · Cited by 108
Ruiz, J., Vicente, C., Haro, C. D., & Bautista, D. K. M. (2013) · Inorganic Chemistry · doi:10.1021/ic302219v · Cited by 99
Self-citationOrganogold(III) Supramolecular Polymers for Anticancer Treatment
Zhang, J., Lu, W., Sun, R. W., & Che, C. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201108466 · Cited by 97
Novel and emerging approaches for the delivery of metallo-drugs
Sánchez-Cano, C., & Hannon, M. J. (2009) · Dalton Transactions · doi:10.1039/b912708a · Cited by 93
Rodrigues, E. G., Silva, L. S., Fausto, D. M., Hayashi, M. S., Dreher, S., dos Santos, E. L., Pesquero, J. B., Travassos, L. R., & Caires, A. C. F. (2003) · International Journal of Cancer · doi:10.1002/ijc.11434 · Cited by 87
Ruiz, J., Rodríguez, V., Cutillas, N., Samper, K. G., Capdevila, M., Palacios, Ò., & Ferao, A. E. (2012) · Dalton Transactions · doi:10.1039/c2dt31654d · Cited by 87
Self-citationZhang, J., Sun, R. W., & Che, C. (2012) · Chemical Communications · doi:10.1039/c2cc00029f · Cited by 87
Synthesis of Cycloruthenated Compounds as Potential Anticancer Agents
Leyva, L., Sirlin, C., Rubio, L., Franco, C., Lagadec, R. L., Spencer, J., Bischoff, P. L., Gaiddon, C., Loeffler, J., & Pfeffer, M. (2007) · European Journal of Inorganic Chemistry · doi:10.1002/ejic.200601149 · Cited by 85
A Potent Ruthenium(II) Antitumor Complex Bearing a Lipophilic Levonorgestrel Group
Ruiz, J., Rodríguez, V., Cutillas, N., Ferao, A. E., & Hannon, M. J. (2011) · Inorganic Chemistry · doi:10.1021/ic201388n · Cited by 81
Self-citationFrezza, M., Dou, Q. P., Xiao, Y., Samouei, H., Rashidi, M., Samari, F., & Hemmateenejad, B. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm2006832 · Cited by 79
Serrano, F. A., Matsuo, A. L., Monteforte, P. T., Bechara, A. H. S., Smaili, S. S., Santana, D. P., Rodrigues, T., Pereira, F. V., Silva, L. S., Machado, J., et al. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-296 · Cited by 74
Baruah, H., Rector, C. L., Monnier, S. M., & Bierbach, U. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)01107-3 · Cited by 74
Vidimar, V., Meng, X., Klajner, M., Licona, C., Fetzer, L., Harlepp, S., Hébraud, P., Sidhoum, M., Sirlin, C., Loeffler, J., et al. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.08.022 · Cited by 70
Li, S. P., Tang, T. S., Yiu, S., & Lo, K. K. (2012) · Chemistry - A European Journal · doi:10.1002/chem.201200979 · Cited by 64
"Platinum on the road": Interactions of antitumoral cisplatin with proteins
Arnesano, F., & Natile, G. (2008) · Pure and Applied Chemistry · doi:10.1351/pac200880122715 · Cited by 63
Iminophosphorane–organogold(III) complexes induce cell death through mitochondrial ROS production
Vela, L., Contel, M., Palomera, L., Azaceta, G., & Marzo, I. (2011) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2011.06.004 · Cited by 62
Specific Blocking of CREB/DNA Binding by Cyclometalated Platinum(II) Complexes
Wang, P., Leung, C., Ma, D., Sun, R. W., Yan, S., Chen, Q., & Che, C. (2011) · Angewandte Chemie International Edition · doi:10.1002/anie.201006887 · Cited by 56
Thioredoxin reductase and cancer cell growth inhibition by organogold(III) compounds
Engman, L., McNaughton, M., Gajewska, M., Kumar, S., Birmingham, A., & Powis, G. (2006) · Anti-Cancer Drugs · doi:10.1097/00001813-200606000-00007 · Cited by 54
Ruiz, J., Vicente, C., Haro, C. D., & Ferao, A. E. (2011) · Inorganic Chemistry · doi:10.1021/ic101526h · Cited by 53
Self-citationBarbosa, C. M. V., Oliveira, C. R., Nascimento, F. D., Smith, M. C. M., Fausto, D. M., Soufen, M. A., Sena, E., Araújo, R. C., Tersariol, I. L. S., Bincoletto, C., et al. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.06.004 · Cited by 51
Chromium(III) complexes inhibit transcription factors binding to DNA and associated gene expression
Sella, R. N., & Nair, B. U. (2008) · Toxicology · doi:10.1016/j.tox.2008.07.052 · Cited by 41
Organometallic Pyridylnaphthalimide Complexes as Protein Kinase Inhibitors
Blanck, S., Cruchter, T., Vultur, A., Riedel, R., Harms, K., Herlyn, M., & Meggers, E. (2011) · Organometallics · doi:10.1021/om200366r · Cited by 39
Inhibition of Janus kinase 2 by cyclometalated rhodium complexes
Leung, C., Yang, H., Ma, V. P., Chan, D. S., Zhong, H., Li, Y., Fong, W. F., & Ma, D. (2012) · MedChemComm · doi:10.1039/c2md00306f · Cited by 34
Pre-clinical antitumour evaluation of Biphosphinic Palladacycle Complex in human leukaemia cells
Oliveira, C. R., Barbosa, C. M. V., Nascimento, F. D., Lanetzki, C. S., Meneghin, M. B. L., Pereira, F. E. G., Paredes‐Gamero, E. J., Ferreira, A. T., Rodrigues, T., Queiroz, M. L. S., et al. (2008) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2008.10.034 · Cited by 31
Diastereomerically pure platinum(II) complexes as antitumoral agents.
Talancón, D., López, C., Font‐Bardía, M., Calvet, T., Quirante, J., Calvis, C., Messeguer, R., Cortés, R., Cascante, M., Baldomà, L., et al. (2012) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2012.09.007 · Cited by 31
Bioactive cyclometalated phthalimides: design, synthesis and kinase inhibition
Blanck, S., Geisselbrecht, Y., Kräling, K., Middel, S., Mietke, T., Harms, K., Essen, L., & Meggers, E. (2012) · Dalton Transactions · doi:10.1039/c2dt30940h · Cited by 27
Liu, J., Sun, R. W., Leung, C., Lok, C., & Che, C. (2011) · Chemical Communications · doi:10.1039/c1cc15317j · Cited by 19
Talib, J., Beck, J. L., Urathamakul, T., Nguyen, C. D., Aldrich-Wright, J. R., Mackay, J. P., & Ralph, S. F. (2009) · Chemical Communications · doi:10.1039/b904751d · Cited by 15
Metadata
- Authors
- Cutillas, N., Yellol, G. S., de Haro, C., Vicente, C., Rodríguez, V., & Ruiz, J.
- Venue
- Coordination Chemistry Reviews
- Publisher
- Elsevier BV
- Published
- 2013-10
- Volume
- 257
- Issue
- 19-20
- Pages
- 2784-2797
- ISSN
- 0010-8545 (ISSN-L)
- OpenAlex
- W1968556710
- Cited by
- 332
- References
- 94
- FWCI
- 14.54
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.